Learn how the immunoSEQ Technology can help you drive your next discovery. Create your free SEQdiscovery account for full access to a growing collection of high-value content, including videos, on-demand webinars, high-impact publications, technotes, and case studies.

Unraveling the role of the adaptive immune system in autoimmune disease

In this webinar, Dr. Katie Boland and Dr. Matt Knight highlight autoimmune diseases, such as multiple sclerosis, type 1 diabetes, Parkinson’s disease, and rheumatoid arthritis and autoimmune-like states, and present data from published studies using the immunoSEQ Technology.

Applications of Immunosequencing in Autoimmunity

This webinar describes how researchers have applied the immunoSEQ® Technology in the context of autoimmune research including applications in diseases such as Crohn's disease, multiple sclerosis, psoriasis, narcolepsy, and alopecia, as well as treatment-induced autoimmunity. Learn how immunosequencing can be used to understand autoimmune disease pathology, response to different treatment modalities, and duration of treatment response.

A role for autoimmunity in Parkinson’s Disease

This webinar provides an overview of the immunoSEQ® Technology and how its quantitative nature enables accurate identification of disease-associated TCRB clones in response to antigen stimulation. It describes how to confidently compare individual repertoires to identify public and private clones, and explores how immunosequencing can be used to understand the immunological mechanisms underlying disease pathogenesis and progression in Parkinson’s disease and potentially inform the development of immunotherapeutics and detection and disease tracking in research.

SARS-CoV-2 variants are escaping neutralizing antibody responses, but have not escaped the T-cell response
– A Johnson & Johnson Case Study

This webinar discusses how the immunoSEQ® T-MAP™ COVID technology was used to measure the T-cell immune response, induced by the Ad26.COV2.S COVID-19 vaccine, and quantify T-cell expansion across all regions of the SARS-CoV-2 virus, including the spike protein.

COVID-19 Emerging themes: T-cell immune responses & immunoSEQ T-MAP COVID applications

At the beginning of 2020, few would have predicted that a global pandemic would turn our daily lives upside down. But a year later, the research community may have a clearer view of what might lie ahead. Throughout 2020, Adaptive Biotechnologies, along with researchers and collaborators around the world, contributed to the massive effort to understand and fight the COVID-19 pandemic. This webinar focuses on what we have learned so far, and emerging research terms for COVID-19.

COVID-19 T-cell Data: Mapping out SARS-CoV-2 Antigen and T-cell Repertoires

In partnership with Microsoft, Adaptive Biotechnologies has created a comprehensive and detailed open access database, ImmuneCODE, that provides COVID-19 data to accelerate ongoing efforts to develop better diagnostics, vaccines, and therapeutics for COVID-19. Here we will discuss the science behind the ImmuneCODE database presented in Nolan et al, some of the applications for which you can analyze the data, use of the immunoSEQ T-MAP COVID service, and initial data insights from the COVID-19 data described in Snyder et al. 

Immune Repertoire Sequencing to Uncover SARS-CoV-2-Specific T-Cell Responses and Dynamics

In this webinar, we discuss the role of T cells in response to SARS-CoV-2 infection an early insights from Adaptive Biotechnologies' open-access ImmuneCODE COVID-19 database, describe the epidemiology of COVID-19 in a cohort of patient samples from Northern Italy, discuss the presence of public SARS-CoV-2-specific clonotypes in COVID-19 patient samples and controls, and analyze differences in the clonal distribution of SARS-CoV-2-specific T cell clonotypes according to different degrees of disease severity. 

T cells in COVID-19: Decoding the Immune Response with Immunosequencing

T cells play a critical role in the adaptive immune system’s response to any virus, including SARS-CoV-2, circulating in the blood to detect and quickly expanding in response to viral challenge, often before symptoms appear. In this webinar, we will discuss the importance of evaluating the T-cell responses from the onset of COVID-19 symptoms through convalescence and the contribution of memory T cells in maintaining durable immunity to SARS-CoV-2.

SARS-CoV-2-Specific T-Cell Map: From Immunosequencing to Data Analysis

In this webinar, we present an overview of Adaptive Biotechnologies' immunoSEQ® Technology, including our new immunoSEQ® T-MAP™ COVID service, the use of robust statistical analyses for COVID-19 data, and how you can easily use the immunoSEQ Analyzer to analyze and visualize your immunosequencing COVID-19 data and integrate it with the ImmuneCODE™ data to gain meaningful insights.

Applications of Gamma/Delta T cells & B cell IgH Sequencing in COVID-19 Research

The COVID-19 pandemic continues to drive an unprecedented worldwide scientific response as we strive to understand the complex immune response elicited by the novel coronavirus SARS-CoV-2. While significant research has focused on the alpha/beta T-cell and neutralizing antibody response to SARS-CoV-2 infection, less attention has been paid to gamma/delta T cells and the broader B-cell response. A complete understanding of COVID-19 pathophysiology requires exploration of the unique contributions gamma/delta T- and B-cells bring to the adaptive immune response.

T Cells in COVID-19: Decoding the Immune Response with Immunosequencing (FOCIS)

In this webinar, we will discuss the role of T-cells in response to COVID-19 and how understanding this immune response can potentially lead to better detection and treatment of COVID-19. We will introduce our comprehensive open access ImmuneCODE™ database that provides COVID-19 data to accelerate ongoing efforts to develop better diagnostics, vaccines, and therapeutics for COVID-19. We will also provide an overview of the immunoSEQ® T-MAP™ COVID offernig and initial data insights from the COVID-19 data.

Unraveling the Immune Response and Utility of a T-Cell Based Test in COVID-19

In this webinar, Harlan Robins, Co-founder and Chief Scientific Officer of Adaptive Biotechnologies, describes the efforts of the company along with researchers and collaborators around the world have taken to understand the SARS-CoV-2 virus and develop better diagnostics and therapuetics for COVID-19. Among these efforts is immunoSEQ® T-MAP™ COVID, which enables researchers to sudy the T-cell immune response to COVID-19. Learn about the current and future research applications of immunoSEQ T-MAP COVID.

Transgenic T-Cell Receptor Adoptive Cell Therapies: Addressing Epigenetic Suppression & Optimizing Therapies with Immunosequencing

This webinar provides a brief overview of immunosequencing with Adaptive Biotechnologies’ immunoSEQ® Technology, and discusses how the immunoSEQ Assay was used to explore epigenetic suppression during transgenic T-cell receptor adoptive cell therapy in melanoma and sarcoma patients.

Utilizing Immunosequencing in Immuno-Oncology and Immunotherapy Research

This webinar aims to provide an overview of Adaptive Biotechnologies’ immunoSEQ® Technology and cloud-based software, immunoSEQ® Analyzer. The webinar will cover functions of the Analyzer software and demonstrate how immunosequencing data can be incorporated into preclinical and clinical research with a focus on immuno-oncology and immunotherapy.

Got FFPE? Immunosequencing with unique & challenging sample types

This webinar provides an overview of the immunoSEQ® Technology and how its quantitative nature makes it uniquely suited to answer questions across numerous research areas. It discusses how to design successful and meaningful immunosequencing research projects with considerations for sample source and preparation, and how the immunoSEQ Assay has been applied in published studies utilizing a wide variety of sample types such as archived formalin-fixed paraffin-embedded (FFPE) tissue, sorted T-cell subsets, urine, ascites, and cell-free DNA.

Approaches to V(D)J Sequencing

The webinar provides an overview of the evolution of V(D)J and CDR3 sequencing approaches and differences in the technologies used for V(D)J sequencing. It outlines the current capabilities of large-scale immunosequencing of T- and B-cell receptors as well as the principles and applications of Adaptive Biotechnologies' quantitative immunoSEQ® Technology and how it can address questions across a wide variety of research topics.

Exploring Repertoire Development and Dynamics with the immunoSEQ® Assay

Immunosequencing, the science of profiling T-cell receptors (TCRs) and B-cell receptors (BCRs), has been widely used to understand how the immune system changes in various disease states and how various treatment modalities impact immune responses. This webinar aims to provide an overview of Adaptive Biotechnologies' immunoSEQ® Technology and its applications in elucidating repertoire generation and dynamics.

Immune Repertoire Data Analysis: From Sequencing Data to Insights

Recent advances in immunosequencing have allowed for accurate quantitation of the T- and B- cell immune repertoire, both in circulating cells and tumor infiltrating T cells. Immunosequencing has been used widely across biological disciplines to both assess changes over time and as a read-out of immune competence. Here we present an overview of Adaptive Biotechnologies' immunoSEQ® Technology and the use of robust statistical analyses across a range of biological fields including oncology and infectious disease.

COVID-19 T-Cell Data: Mapping Out SARS- CoV-2 Antigen & T-Cell Repertoires

In partnership with Microsoft, Adaptive Biotechnologies has created a comprehensive and detailed open access database, ImmuneCODE™, that provides COVID-19 data to accelerate ongoing efforts to develop better diagnostics, vaccines, and therapeutics for COVID-19. Here we will discuss the science behind the ImmuneCODE™ database presented in Nolan et al, some of the applications for which you can analyze the data, use of the immunoSEQ® T-MAP™ COVID offering, and initial data insights from the COVID-19 data described in Snyder et al.

Impact of CMV infection on the T-cell repertoire: Insights from the immunoSEQ Assay

In this webinar, Dr. Paul Fields and Dr. Nate Polaske discuss how the immunoSEQ® Assay has been used to gain mechanistic insights into the effects of CMV infection on T cells, and highlight a T-cell repertoire-based classifier to identify CMV status to better understand CMV infection in a research setting.

Research Applications of the immunoSEQ Assay in Mouse Models

In this webinar, Dr. Richard DiPaolo, from Saint Louis University School of Medicine, will be discussing data generated in his laboratory that used the immunoSEQ Assay along with various bioinformatic approaches to identify and track virus-specific T cells circulating in blood over long periods of time, determine the impact of immunotherapy on tumor-infiltrating T cells, and to quantitate the diversity of T cells specific for peptides from ZIKA virus.

Applications of Immunosequencing in Infectious Disease Research

This webinar will highlight infectious disease and vaccine research, and discuss published studies where immunoSEQ® Technology was leveraged. Topics will include repertoire properties associated with disease and vaccine responses, identifying antigen-specific clones, tracking clones over time and how repertoire and clone-level data can be integrated with clinical data to drive understanding and progress in the field.

Applications of immunoSEQ® in Transplantation Research

This webinar aims to provide an overview of Adaptive Biotechnologies' immunoSEQ® Technology and its applications in the field of transplantation research including applications in hemopoietic stem cell transplant (HSCT), graft-versus-host disease (GVHD), solid organ transplant, and immune reconstitution.

World Vaccine Congress 2021: Emerging themes around the T-cell response & COVID-19

See our panel discussion with Sharon Benzeno, Chief Business Development Officer, and our exhibitor seminar with Harlan Robins, Chief Scientific Officer & Co-founder from the World Vaccine Congress 2021.

Utilizing Immunosequencing in Cancer Research & Drug Discovery

This webinar provides an overview of the immunoSEQ Technology, highlighting key case studies of the immunoSEQ Technology in oncology research, and applications in pre-clinical and clinical research settings. Also discussed is an overview of Adaptive’s drug development capabilities, including identifying and characterizing viable therapeutic targets in solid tumors.

Applications of immunoSEQ® in Vaccine Research

This webinar aims to provide an overview of Adaptive Biotechnologies’ immunoSEQ® Technology and its applications in the field vaccine research. Viewers will learn about the utility of immunosequencing in general vaccine research and how immunoSEQ can be applied to vaccine applications in both infectious disease and cancer settings.

Utilizing the immunoSEQ® Assay in Clinical Trials

To date, there are no good preclinical models for HPV disease. Dr. Connie Trimble’s lab has developed methods to query the cervical mucosal microenvironment at a molecular level, in very small human tissue specimens. Dr. Trimble’s lab has designed and conducted a series of early phase, investigator-initiated clinical trials testing immunotherapies to treat incipient malignancies caused by HPV. Insights gained from longitudinal subject-matched tissue specimens have informed the design and choice of vaccine for each subsequent clinical trial. Data derived from longitudinal, prospectively-obtained, subject-matched specimens obtained from their protocol participants will be discussed.

From Bench to Biomarker: Applications of immunoSEQ Assay Across the Clinical Development Pipeline

Adaptive Biotechnologies’ quantitative immunoSEQ® Technology has the ability to answer early, preclinical questions such as those around drug candidate selection, dosing and effective drug combinations. As a therapeutic pipeline matures to the clinical trial stage, the immunoSEQ Assay can also help confirm drug safety and efficacy, establish biomarker endpoints, optimize patient selection, predict response to therapy and monitor for adverse events. This webinar will use real-world data to demonstrate how immunosequencing can be leveraged at various points in the drug development and clinical trial process to improve the development of new therapies for patients.

Highlights from Adaptive Biotechnologies at AAI 2021

This webinar provides an overview of immunoSEQ Technology and recent publications across research applications such as immuno-oncology, infectious disease, and autoimmune research, including pre-clinical and clinical research.

Highlights from Adaptive Biotechnologies at FOCIS 2021

This webinar provides an overview of the principles behind the Adaptive Biotechnologies immune-medicine platform, particularly the immunoSEQ® Technology, and insights from over a year of COVID-19 research, including identification of public T-cell receptors to detect recent of past T-cell immune response to infection, track responses to vaccines, and study emerging variants. It also discusses the impact of COVID-19 in other therapeutic areas, and explores extensions of the technology into other diseases, from assessing prior CMV infection to possibly detecting Lyme disease and Crohn’s disease.

Thumbnail-Single-cell-vs-Large-scale-Sequencing-Poster
poster

Large-scale vs. single-cell immunosequencing

In this poster you will discover:

  • How the immunoSEQ Assay works
  • How single-cell immunosequencing works
  • Pros and cons to each method including sample type, sample prep, and data analysis